OABIHealthcare · BiotechnologyThe 7 Wall Street analysts covering OmniAb, Inc. hold a median 12-month price target of $8 — +74.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 15 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores OmniAb, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Volatility (33): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OABI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +74.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Leerink Partners | Maintains | Outperform | $10 → $12 |
| 7 Oct 2026 | StoneX | Maintains | Buy | $4.00 → $6.00 |
| 17 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $11 |
| 17 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 7 Aug 2025 | RBC Capital | Maintains | Outperform | $4.00 → $3.00 |
| 12 May 2025 | Benchmark | Reiterates | Buy | — |
| 27 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 20 Mar 2025 | Benchmark | Maintains | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | RBC Capital | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | Benchmark | Reiterates | Buy | — |
| 26 Mar 2024 | Truist Securities | Maintains | Buy | — |
| 22 Mar 2024 | Benchmark | Reiterates | Buy | — |
| 21 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Mar 2024 | RBC Capital | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OABI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, OmniAb, Inc. returned +170.0% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 10% of US stocks
Cheaper than 35% of US stocks
Cheaper than 92% of US stocks
Higher than 96% of US stocks
Higher than 91% of US stocks
Higher than 98% of US stocks
Higher than 17% of US stocks
Higher than 5% of US stocks
Higher than 33% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
OmniAb, Inc. has a market value of $667.3M and an enterprise value of $634.3M.
Revenue in the twelve months to 30 June 2026: $38.5M. The latest quarter grew 244.2% year on year.
Net income over the same four quarters: −$44.3M, a −115.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.36.
Free cash flow in the twelve months to 30 June 2026: −$18.1M.
Trailing P/E: −8.1×; forward P/E: −15.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
OmniAb, Inc. employs 89 people — $432K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own OmniAb, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
OmniAb announced it will report financial results for the three and nine months ended September 30, 2026, before U.S. markets open on October 30, 2026. The company will hold a conference call that day at 8:00 a.m. Eastern time.
Why it matters — OABI watchers can note when the company’s quarterly results will be released and discussed.
At its investor and analyst day, OmniAb outlined plans to expand royalty-bearing partnerships, commercialize its xPloration screening platform and enter peptide discovery with its newly introduced OmniTides platform.
Why it matters — The event detailed strategic initiatives tied to OmniAb’s partnership, platform-commercialization and peptide-discovery efforts.
Seeking Alpha published a transcript of OmniAb, Inc.’s Analyst/Investor Day.
Why it matters — The transcript provides OABI watchers with a record of the company’s Analyst/Investor Day discussion.
OmniAb, Inc. was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The source says this might drive the stock higher in the near term.
Why it matters — OABI watchers may note the improved Zacks rating as an indication of greater optimism about the company’s earnings prospects.
OmniAb is hosting its Investor & Analyst Day in Emeryville, highlighting recent partner developments and the broader rollout of its xPloration® platform. The event also introduces the OmniTides™ peptide discovery platform and brand.
Why it matters — OABI watchers may note the company’s updates on partner activity and its discovery-platform initiatives presented at the event.
The 7 Wall Street analysts covering OmniAb, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering OmniAb, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OmniAb, Inc. 97 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, OmniAb, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +74.3% from the last close, and Ticker Nerd's factor model ranks OmniAb, Inc. 97 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering OmniAb, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OABI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $12 over the next 12 months.
OmniAb, Inc. returned +170.0% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions.
The most recent item we track (Business Wire, 14 Oct 2026): "OmniAb to Report Third Quarter 2026 Financial Results on October 30". OmniAb announced it will report financial results for the three and nine months ended September 30, 2026, before U.S. markets open on October 30, 2026. The company will hold a conference call that day at 8:00 a.m. Eastern time.
OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies and academic institutions. OmniAb’s platform is designed to support the discovery of next-generation therapeutics by creating and screening diverse antibody repertoires, helping partners identify optimal antibodies and other target-binding proteins for drug development. Its current offerings center on proprietary transgenic animal systems and related discovery tools that enable the generation of fully human antibodies and other therapeutic candidates. The company also provides integrated and customizable solutions that combine biological and computational methods, including antigen design, immunization, high-throughput screening, and data analysis. OmniAb serves a broad range of partners across the life sciences industry, positioning itself as a technology provider in the antibody discovery and biologics research market. Headquartered in Emeryville, California, OmniAb focuses on enabling research programs rather than developing and commercializing its own drugs.
CEO Mr. Matthew W. Foehr · 89 employees · United States · https://www.omniab.com
